If you are looking for a reasonable coverage for telaprevir
"... The development timeline for boceprevir is similar to telaprevir, but recent data seems to demonstrate that half the patients receiving Merck’s boceprevir developed anemia. The major side effect of Vertex’s telaprevir is a skin rash, which is not considered a clinically important safety issue, but can impact enrollment....."
Boceprevir isn't a relevant competitor...and it has many more weaknesses that just anemia and the requirement of significant off label EPO use which the FDA won't like due to warnings against EPO use in HCV! The drug also has the following liabilities vs. telaprevir (TVR): - it doesn't work well in null responders (Merck not allowed to even study the drug there) - it will always be a 3 times a day drug vs. a twice daily drug which TVR has shown is possible with their drug - it will have to be used for 48 weeks in most patients (tough for patients) where telaprevir will only need to be used for 24 weeks in the majority of patients. - boceprevir patients will have to wait 2-3 months to know if they have a chance at a cure and they will all know in just 4 weeks on telaprevir.
Which drug would you take???? You don't often see that many advantages for one drug vs. another in the same class!